Genovis Q2 2024: Intial take – softer than anticipated - Redeye

Redeye sees the Q2 report coming in below estimates for both sales and EBIT. Additionally, after market close yesterday, the company announced the divestment of its antibody business. In this note, we provide our initial comments.

Länk till analysen i sin helhet: https://www.redeye.se/research/1030851/genovis-q2-2024-intial-take-softer-than-anticipated?utm_source=finwire&utm_medium=RSS